imatinib mesylate has been researched along with Communicable Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kiyokawa, N; Kiyotani, C; Mori, T | 1 |
| Beverloo, HB; Cornelissen, JJ; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Kluin-Nelemans, HC; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, P; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Westveer, PH; Wijermans, PW; Willemze, R; Wittebol, S | 1 |
| Kano, Y | 1 |
2 review(s) available for imatinib mesylate and Communicable Diseases
| Article | Year |
|---|---|
[Clinical problems in the treatment of myeloid leukemia in childhood].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Communicable Diseases; Down Syndrome; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk | 2009 |
[Adverse drug reactions induced by molecular target therapy].
Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Cetuximab; Communicable Diseases; ErbB Receptors; Etanercept; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Immunoglobulin G; Infliximab; Lung Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Tumor Necrosis Factor; Skin Diseases; Tumor Necrosis Factor-alpha | 2007 |
1 trial(s) available for imatinib mesylate and Communicable Diseases
| Article | Year |
|---|---|
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Communicable Diseases; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hematologic Tests; Humans; Imatinib Mesylate; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mortality; Piperazines; Pyrimidines | 2008 |